

October 5, 2021

To,
Mr. Harshad Naik,
Listing Compliance,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
Mr. Binoy Yohannan
Chief Manager - Surveillance,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Scrip Code: 532296

Scrip Name: GLENMARK

Ref: NSE Letter and e-mail dated October 04, 2021, Ref. No.: NSE/CM/Surveillance/11179
BSE e-mail dated October 04, 2021

Dear Sirs,

Sub: Clarification on news item appearing in "Media/Publication"

This is with reference to your emails dated October 4th, 2021, seeking clarification on the news item appearing on 'www.business-standard.com' dated October 3rd, 2021. In this regard, please find our statement below:

Based on internal assessment, Glenmark's US entity (Glenmark Pharmaceuticals Inc. USA) has voluntarily recalled products mentioned in the news item (Fulvestrant Injection, Naproxen Sodium Tablets, Chlorzoxazone Tablets, Zonisamide Capsules and Arformoterol Tartarate Inhalation Solution) as a matter of abundant caution. We hereby confirm on the matter of the recall of the said products.

Glenmark treats all matters related to quality with utmost seriousness, and will take whatever actions necessary to ensure such quality of products and operational compliance.

This development does not have any material impact on the Company and hence it did not warrant disclosure to the Stock Exchanges, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

Glenmark prides itself on conducting its business with utmost integrity and we have been proactive in informing the Exchange about the material events of the Company.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer

